ADENOSINE FOR PEROPERATIVE BLOOD-PRESSURE CONTROL IN AN INFANT WITH NEUROBLASTOMA

被引:10
作者
SELLDEN, H
KOGNER, P
SOLLEVI, A
机构
[1] KAROLINSKA HOSP,DEPT PAEDIAT,STOCKHOLM,SWEDEN
[2] KAROLINSKA HOSP,DEPT CLIN CHEM,STOCKHOLM,SWEDEN
[3] KAROLINSKA HOSP,DEPT ANAESTHESIA & INTENS CARE,STOCKHOLM,SWEDEN
关键词
ADENOSINE; ANESTHESIA; HYPERTENSION; NEONATAL; NEUROBLASTOMA; NEUROPEPTIDE Y; NOREPINEPRHINE; PEDIATRICS;
D O I
10.1111/j.1399-6576.1995.tb04151.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
We describe a child with a localised pelvic neuroblastoma and a hypertensive crisis during the first weeks of life due to elevated sytemic norepinephrine of tumoural origin. In spite of treatment with high doses of alpha-blockers, blood pressure did not respond fully and the boy had a very unstable circulation. Surgery was performed al one month of age. Adenosine, a potent short-acting vasodilator, was used for peroperative blood pressure control to protect the patient from an uncontrolled hypertensive crisis. During tumour manipulation the child became hypertensive with systolic pressure exceeding 130 mm Hg and adenosine infusion (100 mu g . kg(-1). min(-1)) was started with a prompt normalisation of the blood pressure. Adenosine infusion could be discontinued after tumour removal. Norepinephrine, dopamine, homovanillic acid and vanillylmandelic acid in urine were elevated preoperatively and normalised at follow up. Plasma concentrations of norepinephrine and dopamine were elevated preoperatively. Norepinephrine increased during hypertension due to tumour manipulation. Plasma neuropeptide Y increased during tumour manipulation but still within the normal range for infants. It is concluded that adenosine can be used peroperatively in children with severe hypertension and in this case no adverse effects of adenosine were noted. Furthermore, tumour synthesis and systemic release of norepinephrine, but not neuropeptide Y, contributed to hypertension in this child with neuroblastoma.
引用
收藏
页码:705 / 708
页数:4
相关论文
共 16 条
  • [1] Voute PA, de Kraker J, Hoefnagel CA., Tumours of the sympathetic nervous system: neuroblastoma, ganglioneuroma and phaeochromocytoma, Cancer in children: Clinical management, pp. 226-243, (1992)
  • [2] Deal JE, Sever PS, Barratt TM, Dillon MJ., Pheocromotytoma‐investigation and management of 10 cases, Arch Dis Child, 65, pp. 269-274, (1990)
  • [3] Bertani-Dziedzic LM, Dziedzic SW, Gitlow SE., Catecholamine metabolism in neuroblastoma, Neuroblastoma: Tumor biology and therapy, pp. 69-91, (1990)
  • [4] Holl JW, Anesthesia for gastrointestinal and abdominal wall disorders, Pediatric Anesthesia, pp. 993-1014, (1989)
  • [5] Grondal S, Bindslev L, Sollevi A, Hamberger B., Adenosine: a new antihypertensive agent during pheocromotytoma removal, World J Surg, 12, pp. 581-585, (1988)
  • [6] Sollevi A., Cardiovascular effects of adenosine in man
  • [7] Possible clinical implications, Progr in Neurolbiol, 27, pp. 319-349, (1986)
  • [8] Owall A, Gordon E, Lagerkranser M, Lindqvist C, Rudehill A, Sollevi A., Clinical experience with adenosine for controlled hypotension during cerebral aneurysm surgery, Anaesth Analg, 66, pp. 229-234, (1987)
  • [9] Kogner P, Barbany G, Bjork O, Castello MA, Donfrancesco A, Falkmer UG, Et al., TRK mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors, Prog Clin Biol Res, (1994)
  • [10] Kogner P, Bjork O, Theodorsson O., Neuropeptide Y in neuroblastoma: Increased concentration in metastasis, release during surgery and characterization of plasma and tumor extracts, Med Ped Oncol, 21, pp. 317-322, (1993)